Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Aldesleukin
Synonyms
Therapy Description

Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Aldesleukin Proleukin IL-2|Interleukin-2|IL2 Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01857934 Phase II Doxorubicin Sargramostim Aldesleukin Vincristine Sulfate Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan Therapy for Children With Advanced Stage Neuroblastoma Active, not recruiting USA 0
NCT02796352 Phase II Aldesleukin A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study Terminated USA 0
NCT05628883 Phase I Cyclophosphamide + Fludarabine TBio-4101 Aldesleukin Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Recruiting USA 0
NCT03126916 Phase III Doxorubicin 131I-MIBG Sargramostim Etoposide Melphalan Busulfan Isotretinoin Vincristine Sulfate Cisplatin Cyclophosphamide Thiotepa Dexrazoxane Lorlatinib Carboplatin Aldesleukin Topotecan Dinutuximab Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Active, not recruiting USA | CAN 1
NCT06151847 Phase II Cyclophosphamide + Fludarabine Lifileucel Aldesleukin Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma Recruiting USA 0
NCT03441100 Phase I Cyclophosphamide + Fludarabine Aldesleukin IMA202 TCR-engineered T Cells in NSCLC and HCC Patients Completed USA | DEU 0
NCT03166397 Phase II Cyclophosphamide + Fludarabine Aldesleukin Nivolumab tumor infiltrating lymphocytes Ipilimumab Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients Recruiting ISR 0
NCT03691376 Phase I Melphalan NY-ESO-1 TCR CD4- CD34+ HSC Aldesleukin Autologous NY-ESO-1-specific CD8-positive T cells Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Terminated USA 0
NCT03991741 Phase I Aldesleukin Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors Recruiting USA 0
NCT03215810 Phase I Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT01409174 Phase Ib/II Cisplatin Ipilimumab Aldesleukin Temozolomide Interferon alpha-2b IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma Terminated USA 0
NCT06236425 Phase I Cisplatin + Pembrolizumab Aldesleukin Carboplatin + Fluorouracil + Pembrolizumab TBio-4101 Cyclophosphamide + Fludarabine Cisplatin + Fluorouracil + Pembrolizumab TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC Recruiting USA 0
NCT02621021 Phase II Pembrolizumab Cyclophosphamide Fludarabine Aldesleukin A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab Suspended USA 0
NCT00338377 Phase II Cyclophosphamide + Fludarabine Aldesleukin Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma Active, not recruiting USA 0
NCT04551885 Phase I Cyclophosphamide + Fludarabine Avelumab + FT516 Aldesleukin FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05883449 Phase II AB-101 + AFM13 Aldesleukin Cyclophosphamide + Fludarabine Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) Recruiting USA 0
NCT05681780 Phase Ib/II Cyclophosphamide + Fludarabine Aldesleukin Nivolumab CD40L-augmented TILs Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC Recruiting USA 0
NCT02027935 Phase II Aldesleukin Cyclophosphamide Ipilimumab Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 Completed USA 0
NCT01993719 Phase II Pembrolizumab Aldesleukin Fludarabine Cyclophosphamide Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma Completed USA 0
NCT03224871 Phase I Pembrolizumab Aldesleukin Nivolumab A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. Completed USA 0
NCT02620865 Phase Ib/II Paclitaxel Aldesleukin Oxaliplatin Sargramostim Gemcitabine Fluorouracil + Leucovorin Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed USA 0
NCT06190249 Phase I Cyclophosphamide + Fludarabine Lifileucel Pembrolizumab Aldesleukin Mesna Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma Suspended USA 0
NCT01038778 Phase Ib/II Entinostat Aldesleukin Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Active, not recruiting USA 0
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Terminated USA 0
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT02118285 Phase I Aldesleukin Epacadostat Cyclophosphamide Fludarabine Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Completed USA 0
NCT01640301 Phase Ib/II Aldesleukin WT1 sensitized T cells Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant Terminated USA 0
NCT03056599 Phase I Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma Completed USA 0
NCT01593670 Phase II Decitabine Aldesleukin Vorinostat Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes Completed USA 0
NCT01659151 Phase II Aldesleukin Fludarabine Vemurafenib Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma Active, not recruiting USA 0
NCT03190941 Phase Ib/II Cyclophosphamide anti-KRAS G12V mTCR cells Fludarabine Aldesleukin Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Recruiting USA 0
NCT01258855 Phase II Aldesleukin Aflibercept Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Completed USA 0
NCT02774291 Phase I Aldesleukin Cyclophosphamide + Fludarabine Filgrastim Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1 Terminated USA 0
NCT01701674 Phase I Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Active, not recruiting USA 0


Additional content available in CKB BOOST